ANGPTL2 ‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion
Molecular Oncology · 2023-12 · 17 (12) · 2637-2658
DOI: 10.1002/1878-0261.13490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 07.08.2023. Verfasst von Tsuyoshi Kadomatsu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care, Kato Memorial Bioscience Foundation, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Loss or downregulation of major histocompatibility complex class I (MHC‐I) contributes to tumor immune evasion. We previously demonstrated that angiopoietin‐like protein 2 (ANGPTL2) promotes tumor progression using a Xp11.2 translocation renal cell carcinoma (tRCC) mouse model. However, molecular mechanisms underlying ANGPTL2 tumor‐promoting activity in the tRCC model remained unclear. Here, we report that ANGPTL2 deficiency in renal tubular epithelial cells slows tumor progression in the tRCC mouse model and promotes activated CD8 + T‐cell infiltration of kidney tissues. We also found that Angptl2 ‐deficient tumor cells show enhanced interferon γ‐induced expression of MHC‐I and increased susceptibility to CD8 + T‐cell‐mediated anti‐tumor immune responses. Moreover, we provide evidence that the ANGPTL2‐α5β1 integrin pathway accelerates polycomb repressive complex 2‐mediated repression of MHC‐I expression in tumor cells. These findings suggest that ANGPTL2 signaling in tumor cells contributes to tumor immune evasion and that suppressing that signaling in tumor cells could serve as a potential strategy to facilitate tumor elimination by T‐cell‐mediated anti‐tumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Japan.
- Center for Metabolic Regulation of Healthy Aging (CMHA), Graduate School of Medical Sciences, Kumamoto University, Japan.
- Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Japan.
- Department of Aging and Geriatric Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan.
- Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan.
- Department of Dermatology and Plastic Surgery, Graduate School of Medical Sciences, Kumamoto University, Japan.
ORCID-Profile: Tsuyoshi Kadomatsu, Yuichi Oike
Förderung
- Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
- Kato Memorial Bioscience Foundation
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Kadomatsu, T., Hara, C., Kurahashi, R., Horiguchi, H., Morinaga, J., Miyata, K., Kurano, S., Kanemaru, H., Fukushima, S., Araki, K., Baba, M., Linehan, W. M., Kamba, T., & Oike, Y. (2023). ANGPTL2 ‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion. Molecular Oncology, 17(12), 2637-2658. https://doi.org/10.1002/1878-0261.13490
Vancouver
Kadomatsu T, Hara C, Kurahashi R, Horiguchi H, Morinaga J, Miyata K, et al. ANGPTL2 ‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion. Molecular Oncology. 2023;17(12):2637-2658. doi:10.1002/1878-0261.13490
BibTeX
@article{Kadomatsu2023,
author = {Kadomatsu, Tsuyoshi and Hara, Chiaki and Kurahashi, Ryoma and Horiguchi, Haruki and Morinaga, Jun and Miyata, Keishi and Kurano, Sohtaro and Kanemaru, Hisashi and Fukushima, Satoshi and Araki, Kimi and Baba, Masaya and Linehan, W Marston and Kamba, Tomomi and Oike, Yuichi},
title = {ANGPTL2 ‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion},
journal = {Molecular Oncology},
year = {2023},
volume = {17},
number = {12},
pages = {2637--2658},
doi = {10.1002/1878-0261.13490}
}
EUVIMED